Late CMV disease remains a major concern in allogeneic BMT recipients. Few surveillance data are available on the occurrence of CMV infection and recurrences after day ؉100. We evaluated the occurrence of antigenemia (AG) recurrences until day ؉365 in 76 patients who received pre-emptive ganciclovir (GCV) therapy prompted by AG у2 positive cells. Sixty-two episodes of AG recurrences were detected in 33 of the 52 patients who had positive AG. Survival analysis showed a 45.4% probability of AG recurrence on day ؉100, 64.8% on day ؉180 and 71.2% on day ؉365. The median time for AG recurrences was 113 (35 to 343) days. Thirty-five of the 62 episodes (56.4%) occurred after day ؉100. More than 70% of the patients responded to a 2-week course of GCV and no CMV disease was observed shortly after discontinuation of GCV. The Cox proportional model showed a significant effect of AG recurrences on patient's follow-up only when the patient developed chronic GVHD (P ‫؍‬ 0.012). Extended surveillance favored early introduction of GCV and late CMV pneumonia occurred in only one of the 76 patients (1.3%). AG recurrences are frequent after day ؉100 and extended surveillance until day ؉365 is recommended for patients who develop chronic GvHD. Bone Marrow Transplantation (2001) 28, 1053-1059. Keywords: antigenemia; CMV; BMT; extended surveillance; late CMV disease In the last decade, major advances have been made in the control of cytomegalovirus (CMV) infection after allogeneic bone marrow transplantation (BMT). These advances were based on early therapeutic interventions with ganciclovir (GCV): general prophylaxis for seropositive patients or for those seronegative with a seropositive donor
and pre-emptive therapy. Pre-emptive interventions dictated by the detection of CMV in bronchoalveolar lavage fluid or in blood, using sensitive techniques such as antigenemia (AG) or molecular assays, significantly reduced CMVrelated morbidity and mortality in these patients. [1] [2] [3] Both strategies focused on the first 100 days after transplantation and after that most of the published series have screened for CMV infection or disease only in the presence of symptoms. [3] [4] [5] [6] [7] Therefore, few surveillance data are available on the occurrence of CMV infection and recurrences after day +100. 8 However, some reports have suggested that the prolonged use of ganciclovir may inhibit the development of CMV-specific T cell responses promoting the occurrence of CMV infection and disease after discontinuation of antiviral therapy. 3, 5, 9 Late CMV disease (after day +100) remains a major concern in allogeneic BMT recipients since mortality rates greater than 50% have been recently described. 3, 6 In the present study, we evaluated the probability of antigenemia recurrences and the occurrence of late CMV disease in patients submitted to extended antigenemia surveillance and pre-emptive GCV therapy, during the first year after BMT.
Patients and methods

Patients
Seventy-five consecutive patients with follow-up longer than 30 days given 76 allogeneic BMT and extended antigenemia surveillance were eligible for the study. Fiftyseven patients had a follow-up greater than 100 days and could be evaluated regarding the occurrence of chronic GVHD and late CMV disease. Only one patient and his donor were CMV seronegative pre-BMT. In 70 BMT, both recipients and donors were seropositive and in five BMT, the recipients were seropositive with a seronegative donor. All patients but two received BMT from a HLA-identical sibling. No patient received a T cell-depleted BMT. Patients' characteristics are shown in Table 1 . a a Evaluated in 57 patients with survival greater than 100 days. TBI = total body irradiation; ALL = acute lymphocytic leukemia; AML = acute myelogenous leukemia; CML = chronic myelogenous leukemia; SAA = severe aplastic anemia; CR = complete remission.
Extended CMV antigenemia surveillance
Blood samples were taken once a week from conditioning until day +120 and at least once a month until 1 year after BMT. During the entire follow-up, whenever a positive AG was detected, the test was repeated every other day until AG resolved. The antigenemia assay was performed according to Van der Bij et al 10 with minor modifications.
11,12
Definitions
Active CMV infection was defined by the presence of at least one episode of positive CMV antigenemia. Positive antigenemia was defined by the detection of one or more peroxidase-positive (dark-brown nuclear staining) cells in 300 000 polymorphonuclear (PMN) leukocytes. Antigenemia recurrence was defined by the appearance of a new episode of positive antigenemia during follow-up. Late CMV infection and disease were defined as CMV infection or disease occurring after day +100. CMV disease was defined according to Ljungman and Plotkin. 13 Diagnosis and clinical grading of acute and chronic GHVD were performed according to Thomas et al 14 and Shulman et al, 15 respectively.
Pre-emptive ganciclovir therapy
When AG у2 positive cells were detected, the patient started pre-emptive intravenous GCV therapy at a dose of 5 mg/kg twice daily for 14 days. If AG remained positive after 7 days, GCV was continued to complete 21 days of therapy, or until AG returned to negative. In patients with AG Ͻ2 positive cells, GCV was not started and the patients were closely monitored for antigenemia levels. No secondary prophylaxis with GCV was used after pre-emptive therapy. When CMV disease was diagnosed, the patients were treated with GCV at the same dose as that used in preemptive therapy. No intravenous immunoglobulin was added to the treatment of CMV disease. 16 
Statistical analysis
Survival analysis was used to calculate the probability of AG detection and AG recurrences during the first year after BMT (Kaplan-Meier). To determine the probability of AG detection or recurrence until day +365, an event was considered the occurrence of positive AG or recurrence, respectively. The absence of AG detection or recurrence was censored at the end of follow-up (day +365) or at the day of patient's death. The occurrence of AG recurrences was evaluated in 52 patients who had at least one episode of positive antigenemia. Logistic regression was used to evaluate the impact of the number of positive cells in the first episode of AG on the appearance of recurrences.
In order to investigate the effect of AG recurrence on patients' follow-up, a competing risk analysis was performed. The competing events were: chronic GVHD, death by other causes and the end of the study without developing chronic GVHD. The analysis was performed by fitting a Cox proportional hazards model, computing the covariance matrix via a robust method and allowing for covariances to be non-zero, as described by Therneau and Grambsch. 17 The best fit was obtained by a model which included, as covariates, the following: time of first positive AG, time of AG recurrences, treatment, time of developing acute GVHD.
To evaluate the effect of AG recurrence on whether the patient developed chronic GVHD or not, we created two new variables: AG recurrence 1 (equal to AG recurrence for patients who developed chronic GVHD, and equal to zero otherwise) and AG recurrence 2 (equal to AG recurrence for patients who did not develop chronic GVHD, and equal to zero otherwise). A Cox proportional hazards model considering the same covariates as above was fitted to the data. 16 
Results
Until day +100, 1227 samples were tested for CMV antigenemia (median 17 tests per patient, ranging from 6 to 22). After day +100, 950 samples were tested until day +365 (median 16 per patient). To evaluate the impact of a closer interval between samples on the incidence of recurrences after day +100, we selected only patients with survival у365 days to analyze a population with the same follow-up (8 months). Among the 52 patients at risk for AG recurrences, 37 were alive at day +365. In an 8-month follow-up, we compared the patients giving up to 16 samples (р2 per month) and those giving more than 16 samples (Ͼ2 per month). The occurrence of AG recurrences was statistically similar in both groups, showing no impact on the incidence of recurrences in patients who gave more than two AG tests per month after day +100 (P = 0.85).
A total of 114 episodes of positive AG were detected until day +365, including first episodes and recurrences.
First episodes
Active CMV infection as detected by positive AG was observed in 52 patients and the median time for its occurrence was 42 days (5 to 362 days). Four patients presented the first episode of positive antigenemia after day +100 (days +123, +128, +224 and +362). The probability of antigenemia detection was 67.7% on day +100, 71.1% on day +180 and 73.2% on day +365 (Table 2 and Figure 1 ).
Thirty-five of the 52 patients (67.3%) had AG у2 cells and therefore received pre-emptive therapy. Sixteen patients with AG Ͻ2 cells were not treated and only one developed CMV disease (CMV-GI diagnosed 7 days after the appearance of positive AG). The remaining one received pre-emptive GCV therapy for 14 days because of receiving an unrelated marrow donor transplant.
Among the 37 patients who received GCV therapy, 28 (75.7%) were treated for 2 weeks and eight patients (21.6%) for 3 weeks. The remaining patient (2.7%) received GCV until AG turned to negative (4 weeks), according to the study protocol. Bone Marrow Transplantation
Recurrences
Thirty-three of the 52 patients who had positive AG presented 62 episodes of AG recurrences (mean 2 per patient, ranging from 1 to 5 recurrences). Sixteen patients had one AG recurrence and 17 had two or more AG recurrences and therefore received multiple courses of GCV. Eleven patients (33.3%) had recurrences before day +100, 11 (33.3%) had AG recurrences after day +100 and 11 patients (33.3%) had recurrences before and after day +100 (Figure 2 ). The median time for the AG recurrences was 113 days (35 to 343 days). The probability of antigenemia recurrence was 45.4% on day +100, 64.8% on day +180 and 71.2% on day +365 (Table 2 and Figure 1 ). Ganciclovir was not introduced in 17 patients who had 21 episodes of one positive cell AG recurrences. Eleven of these patients (64.7%) had 13 episodes of recurrences after day +100. None of these patients developed CMV disease despite not receiving GCV.
The remaining 41 episodes of AG у2 cells occurred in 16 patients and the duration of pre-emptive GCV therapy was 2 weeks in 29 episodes (70.7%) and 3 weeks in 12 episodes (29.3%). Fifteen of these patients (93.7%) had 22 episodes of AG recurrences after day +100. Thus, 35 of the 62 episodes of AG recurrences (56.4%) occurred after day +100. Pre-emptive (AG-guided) ganciclovir therapy was started in 22 of the 35 episodes (62.8%) of late CMV reactivation.
In the remaining 13 episodes (AG Ͻ2 cells), the patients were closely monitored for AG levels but no GCV was added (Figure 2 ). None of the latter patients developed CMV disease.
Higher numbers of positive cells at first positive antigenemia did not correlate with more recurrences as demonstrated by logistic regression (P Ͼ 0.10).
Acute and chronic GVHD
Acute GVHD grade уII was diagnosed in 47 of the 76 patients (61.8%). Among the 57 patients with survival longer than 100 days, 33 patients (57.9%) developed chronic GVHD. Five patients had limited chronic GVHD and 28 had extensive chronic GVHD (one 'de novo', eight Bone Marrow Transplantation quiescent and 19 progressive). The Cox proportional model to evaluate the impact of chronic GVHD on AG recurrences showed that AG recurrences had a significant effect on the patient's follow-up only when the patient developed chronic GVHD (Table 3) . The Wald and score tests lead to P values of 0.000129 and 0.00299, respectively, indicating that the Cox model fit was acceptable.
CMV disease
During the first year after BMT, CMV disease was diagnosed in 11 of the 76 patients (14.4%) and the median time for its occurrence was 44 days (range 35 to 197 days). Three patients had CMV-IP and eight had CMV-GI. Seven patients were already receiving GCV because of a previous or concurrent positive antigenemia when CMV disease was diagnosed. Three patients did not have a concurrent positive AG when CMV disease was diagnosed and in one patient CMV-GI preceded positive AG by 6 days. Only one out of the 57 patients (1.7%) surviving day +100 developed late CMV-IP. This patient was already receiving GCV for AG recurrence detected on day +190 when CMV-IP was diagnosed on day +197 and responded to a 3-week course of ganciclovir ( Figure 3 , patient No. 36).
CMV disease was treated with GCV for 2 weeks in eight of the 11 patients (72.7%). The remaining three patients who had CMV gastritis were treated for 3 weeks.
No CMV-related death was observed in this group of patients exposed to extended antigenemia surveillance and pre-emptive GCV therapy.
Discussion
The data shown in the present study demonstrate that antigenemia recurrences are quite common during the first year after BMT. The overall probability of AG recurrences was 71.2% in this group of patients exposed to extended antigenemia surveillance.
The occurrence of active CMV infection during the first 100 days after transplant has been extensively demonstrated as well as the time of its occurrence. Several studies have shown that CMV surveillance using more sensitive techniques such as antigenemia or PCR has detected CMV reactivation around day +40, whereas surveillance based on 'shell-vial' cultures has detected CMV infection around day +50.
2,8,18-21
The incidence of CMV disease before day +100 was 13.1% in the present series. This probably reflects our pol- icy of pre-emptive GCV therapy prompted by AG у2 cells and less likely a lack of sensitivity of the antigenemia assay. Other authors have observed similar incidences of CMV disease in pre-emptive therapy guided by antigenemia. 3, 22 Lower incidences of early onset CMV disease (3.8% and 3%, respectively) have been observed in centers adopting pre-emptive strategies guided by any level positive antigenemia or more sensitive assays like PCR. 7, 8 However, these centers have observed a higher incidence of late CMV disease (13.1% and 10%, respectively). 7, 8 We also observed that CMV antigenemia did not necessarily predict the occurrence of CMV-GI until day +100. Three of the eight patients (37.5%) with CMV-GI did not have a concurrently positive AG. Other authors have observed similar findings. 3, 22 Local viral replication without viremia is probably the reason for this observation. 23 Few studies have been conducted to evaluate routinely the occurrence of CMV infection after day +100. 8 In the present series, the median time for the first AG detection was 42 days ranging from 5 to 365 days, confirming previous reported data and emphasizing the importance of CMV surveillance until day +100, mainly in BMT centers adopting pre-emptive GCV strategy. However, we observed an increase of 25.8% in the probability of AG recurrences after day +100 (from 45.4% on day +100 to 71.2% on day +365), suggesting that extended surveillance may be necessary to identify the patients at risk for developing late CMV disease and to ensure the introduction of pre-emptive GCV therapy.
If no secondary GCV prophylaxis is added after preemptive therapy, AG recurrence rates around 30% are expected to occur until day +100.
3, 8 We observed that 15 of the 48 patients (31.3%) who had positive AG before day +100 required treatment as dictated by AG recurrence. Likewise, Boeckh et al 3 observed AG recurrences in 30% of the BMT recipients given pre-emptive GCV therapy promoted by the appearance of AG у3 cells. Einsele et al 8 found that 33% of patients required retreatment until day +100 because of a second CMV reactivation as detected by PCR. Although the occurrence of late CMV disease was carefully evaluated in the latter series, no PCR surveillance was performed after day +100 and the proportion of patients who would benefit from receiving pre-emptive PCR-guided GCV therapy during the first year after BMT, could not be determined. 8 Concerning the occurrence of AG recurrences after day +100, we observed that 16 of the 22 patients (72.7%) with late recurrences required pre-emptive GCV therapy because of AG у2 cells (Figure 2 ). All patients were successfully Patient No.
< Day +100 > Day +100   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51 treated and only one of the 76 patients (1.3%) in the present study developed late CMV-IP. BMT centers performing unrelated marrow transplants are expected to detect even higher rates of AG recurrences reflecting the increased rates of GVHD observed in this population.
Incidences of late CMV disease ranging from 5% to 10% have been described in other series that did not perform any CMV surveillance or used less sensitive techniques after day +100. [3] [4] [5] [6] 8 These data suggest that the extended AG surveillance performed in our study, may have played an important role in preventing the development of late CMV disease.
Considering the effects of GCV on CMV-specific T helper cell recovery, even higher incidences of late CMV disease could be predicted in BMT centers that adopt general prophylaxis or pre-emptive GCV strategies followed by secondary prophylaxis until day +100. The reactivation of CMV infection after BMT is a powerful stimulus for the Bone Marrow Transplantation development of the CMV-specific T cell response. 9 Suppressing CMV reactivation, the prolonged use of GCV during prophylaxis or pre-emptive therapy may abort the induction to CMV immune reconstitution that is necessary to protect patients from developing late CMV disease. Indeed, adjusting pre-emptive GCV strategy to start at any AG level and continuing until day +100, Boeckh et al observed that 3.8% of patients developed CMV disease during the first 100 days, as compared to 14.1% of the patients who had received intermittent courses of GCV prompted by AG у3 cells. However, the incidences of late CMV disease increased from 8.3% to 13.1%, during intermittent pre-emptive therapy or secondary GCV prophylaxis, respectively. 7 In a randomized trial, the authors observed a 16.5% incidence of late CMV disease in the group exposed to GCV prophylaxis at engraftment. 3 Einsele et al 8 observed that patients who received more than 4 weeks of pre-emptive therapy had a 22.9% risk of developing late CMV disease vs 2% for those receiving р4 weeks of GCV.
These data clearly demonstrate that the more GCV is used until day +100, the higher the incidence of late CMV disease. In fact, the immediate consequence of those strategies is only a delay in the time of occurrence of CMV disease. Comparing the events of CMV-IP in patients receiving early treatment (only if CMV disease was diagnosed) or intermittent pre-emptive GCV therapy (notably more courses of GCV), we observed that the median time for the occurrence of CMV pneumonia moved from 55 to 92 days. 16 In centers adopting GCV prophylaxis, some authors have described the occurrence of CMV-IP as late as 237 days after BMT (mean day of onset). 6 Another topic subject to discussion and not well-defined yet is related to the duration of GCV therapy. In the present study, more than 70% of patients responded to a 2-week GCV course regardless of having first episodes or recurrences and no CMV disease was observed shortly after discontinuation of GCV therapy. We treated each episode of AG у2 cells with 5 mg/kg twice a day for 2 weeks, prolonging therapy for 1 more week if AG remained positive у7 days after starting GCV, as proposed by Vlieger et al. 24 Using the same GCV doses for 2 weeks to treat CMV reactivation detected by PCR, other authors have observed similar findings. 8 On the other hand, treating the episodes of AG у3 cells with 5 m/kg of GCV twice a day for 7 days and then decreasing to 5 mg/kg once a day for 7 more days or until cessation of antigenemia, Boeckh et al 3 observed that 7.7% of patients developed CMV disease shortly after discontinuation of GCV. These data suggest that if intermittent pre-emptive therapy is adopted, intravenous GCV at a dose of 5 mg/kg twice a day for at least 2 weeks should be recommended to treat the reactivation episodes. All these observations confirm previous reported data about the value of the AG test to monitor the duration of therapy and mainly to prevent unnecessary use of GCV. 16, 22, 24 We also observed that 32.4% of the AG episodes (both first and recurrent episodes) did not require GCV treatment (AG Ͻ2 cells) and undesirable antiviral side-effects could be avoided. It is important to stress that we prepared the AG slides with 300 000 polymorphonuclear leukocytes while other groups usually prepare slides with 50 000 to 200 000 PMN. In addition, close monitoring of these patients is needed to detect increasing AG levels which demands a good compliance in the follow-up. Taking advantage of the quantitative nature of the antigenemia test, some authors have successfully limited pre-emptive therapy according to the grade of acute GVHD and AG levels. 22 Chronic GVHD seems to be the most important risk factor for late CMV reactivation and CMV disease. Krause et al 5 observed that chronic GVHD markedly delayed the proliferative response to CMV and suggested that patients lacking a CMV-specific T helper cell response at day +100 might benefit from sensitive screening for CMV infection and pre-emptive therapy after day +100. Nguyen et al 6 observed that among patients with late CMV-IP, 92% had chronic GVHD or had received T cell-depleted transplants. Einsele et al 8 evaluating the risk factors for treatment failures in PCR-guided pre-emptive therapy found chronic GVHD as one of the risk factors for late onset CMV disease. In the present series, we also observed that the incidence of AG recurrences was higher in patients who developed chronic GVHD. As a result of our policy of extended surveillance, late CMV-IP was diagnosed in only one patient, and extended AG surveillance favored earlier introduction of GCV therapy.
We conclude that episodes of late CMV reactivation as detected by antigenemia are common after day +100. Extended AG surveillance is strongly recommended during the first year after BMT for patients who develop chronic GVHD. Patients without chronic GVHD might also benefit from AG surveillance until day +180. BMT centers adopting prophylaxis at engraftment or secondary prophylaxis after pre-emptive therapy are more likely to observe late CMV disease and should carefully consider extended surveillance with sensitive techniques to ensure early and successful GCV therapy.
